Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Management

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Insider Transactions
      • Stock Ownership
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Management

Show all
Michael H. Tardugno
Executive Chairman, President and Chief Executive Officer
MHT image

Michael H. Tardugno's career has been exclusively focused in healthcare with 30 years of experience in the pharmaceutical and medical device industries. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations. Mr. Tardugno holds a BS from St. Bonaventure University and attended the Harvard Business School executive program.
 

    Khursheed Anwer, PhD, MBA
    Executive Vice President and Chief Scientific Officer
    KA image

    Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Scientific Officer, EGEN, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Scientific Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

      Nicholas Borys, MD
      Vice President and Chief Medical Officer
      NB image
      Nicholas Borys, MD joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc, has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology while holding increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an MD Degree from American University of the Caribbean.
        Jeffrey W. Church, CPA
        Chief Financial Officer and Senior Vice President, Corporate Business Strategy and Investor Relations
        JC image

        Jeffrey W. Church was appointed Senior Vice President, Corporate Strategy and Investor Relations on July 8, 2011. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. Mr. Church brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining the Company, Mr. Church held senior financial executive positions with several private and public clinical stage Life Science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm, Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

          For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

            Shareholder Tools

            • Printed Materials
            • Email Alerts
            • Downloads
            • RSS
            • Print
            • Search

            • Facebook
            • Google
            • LinkedIn
            • Twitter
            • RSS

          Home

          Technology

          Products

          Pipeline

          Disease

          Publications

          News & Investors

          About Us

          Careers

          Privacy Policy

            ThermoDox is a registered trademark of Celsion Corporation.
            TheraPlas and TheraSilence are trademarks of Celsion Corporation.
            Avastin is a registered trademark of Genentech, Inc.
            Copyright © 2021 Celsion Corporation. All rights reserved.

            Share This
            • Twitter
            • Google+
            • Facebook
            • LinkedIn